Kohek P H, Pakisch B, Glanzer H, Höss G, Mischinger H J, Wolf G, Steindorfer P
Department of Surgery, University of Graz, Austria.
Eur J Surg Oncol. 1995 Dec;21(6):627-31. doi: 10.1016/s0748-7983(95)95391-4.
Forty-eight patients with non-resectable cancer of the oesophagus and oesophagogastric junction (Group A: Stage I/II, 32; Group B: Stage III/IV, 16) underwent intraluminal Iridium-192 high dose-rate afterloading therapy (5-7 Gy/session, total dose: 5-21 Gy, mean: 12.4 Gy) and external beam irradiation (Karnofsky > or = 80% 50-60 Gy/2 Gy per day; Karnofsky 60-79%: 30 Gy/3 Gy per day). Durable satisfactory palliation (intake of at least semi-solid food) was demonstrated in 96% of patients. The mean survival for group A was 19.1 months and that for group B, 6.9 months, with a 12-month survival rate of 66% (group A) and 0% (group B) (P < 0.001). Local tumour response and complication rate were significantly dose-related with a predicted response rate of 70.5%, and a complication rate of 50% at ERD 129.3 Gy.
48例不可切除的食管癌和食管胃交界癌患者（A组：Ⅰ/Ⅱ期，32例；B组：Ⅲ/Ⅳ期，16例）接受腔内铱-192高剂量率后装治疗（每次5 - 7 Gy，总剂量：5 - 21 Gy，平均：12.4 Gy）及外照射（卡氏评分≥80%：50 - 60 Gy，每天2 Gy；卡氏评分60 - 79%：30 Gy，每天3 Gy）。96%的患者获得了持久的满意姑息效果（至少能摄入半固体食物）。A组的平均生存期为19.1个月，B组为6.9个月，12个月生存率A组为66%，B组为0%（P < 0.001）。局部肿瘤反应和并发症发生率与剂量显著相关，预计反应率为70.5%，在等效生物剂量129.3 Gy时并发症发生率为50%。
